These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 20207521)

  • 1. Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial.
    Narula PK; Rehan HS; Unni KE; Gupta N
    Schizophr Res; 2010 May; 118(1-3):218-23. PubMed ID: 20207521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Melatonin for prevention of metabolic side-effects of olanzapine in patients with first-episode schizophrenia: randomized double-blind placebo-controlled study.
    Modabbernia A; Heidari P; Soleimani R; Sobhani A; Roshan ZA; Taslimi S; Ashrafi M; Modabbernia MJ
    J Psychiatr Res; 2014 Jun; 53():133-40. PubMed ID: 24607293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study.
    Wu RR; Zhao JP; Guo XF; He YQ; Fang MS; Guo WB; Chen JD; Li LH
    Am J Psychiatry; 2008 Mar; 165(3):352-8. PubMed ID: 18245179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial.
    Baptista T; Martínez J; Lacruz A; Rangel N; Beaulieu S; Serrano A; Arapé Y; Martinez M; de Mendoza S; Teneud L; Hernández L
    Can J Psychiatry; 2006 Mar; 51(3):192-6. PubMed ID: 16618011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Weight gain, metabolic parameters, and the impact of race in aggressive inpatients randomized to double-blind clozapine, olanzapine or haloperidol.
    Krakowski M; Czobor P; Citrome L
    Schizophr Res; 2009 May; 110(1-3):95-102. PubMed ID: 19269139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.
    McQuade RD; Stock E; Marcus R; Jody D; Gharbia NA; Vanveggel S; Archibald D; Carson WH
    J Clin Psychiatry; 2004; 65 Suppl 18():47-56. PubMed ID: 15600384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol.
    Saddichha S; Ameen S; Akhtar S
    J Clin Psychopharmacol; 2008 Feb; 28(1):27-31. PubMed ID: 18204337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.
    Kinon BJ; Basson BR; Gilmore JA; Tollefson GD
    J Clin Psychiatry; 2001 Feb; 62(2):92-100. PubMed ID: 11247108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study.
    Poyurovsky M; Tal V; Maayan R; Gil-Ad I; Fuchs C; Weizman A
    Eur Neuropsychopharmacol; 2004 Aug; 14(4):332-6. PubMed ID: 15163444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
    Simpson GM; Glick ID; Weiden PJ; Romano SJ; Siu CO
    Am J Psychiatry; 2004 Oct; 161(10):1837-47. PubMed ID: 15465981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain.
    Ko YH; Joe SH; Jung IK; Kim SH
    Clin Neuropharmacol; 2005; 28(4):169-75. PubMed ID: 16062095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naïve population.
    Perez-Iglesias R; Mata I; Pelayo-Teran JM; Amado JA; Garcia-Unzueta MT; Berja A; Martinez-Garcia O; Vazquez-Barquero JL; Crespo-Facorro B
    Schizophr Res; 2009 Feb; 107(2-3):115-21. PubMed ID: 18993033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study.
    Poyurovsky M; Isaacs I; Fuchs C; Schneidman M; Faragian S; Weizman R; Weizman A
    Am J Psychiatry; 2003 Feb; 160(2):297-302. PubMed ID: 12562576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of long-term (at least 24 weeks) weight gain and metabolic changes between adolescents and adults treated with olanzapine.
    Kryzhanovskaya LA; Xu W; Millen BA; Acharya N; Jen KY; Osuntokun O
    J Child Adolesc Psychopharmacol; 2012 Apr; 22(2):157-65. PubMed ID: 22372514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial.
    Kryzhanovskaya L; Schulz SC; McDougle C; Frazier J; Dittmann R; Robertson-Plouch C; Bauer T; Xu W; Wang W; Carlson J; Tohen M
    J Am Acad Child Adolesc Psychiatry; 2009 Jan; 48(1):60-70. PubMed ID: 19057413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rosiglitazone in the assistance of metabolic control during olanzapine administration in schizophrenia: a pilot double-blind, placebo-controlled, 12-week trial.
    Baptista T; Rangel N; El Fakih Y; Uzcátegui E; Galeazzi T; Beaulieu S; Araujo de Baptista E
    Pharmacopsychiatry; 2009 Jan; 42(1):14-9. PubMed ID: 19153941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of open-label, 8-week trials of olanzapine monotherapy and topiramate augmentation of olanzapine for the treatment of pediatric bipolar disorder.
    Wozniak J; Mick E; Waxmonsky J; Kotarski M; Hantsoo L; Biederman J
    J Child Adolesc Psychopharmacol; 2009 Oct; 19(5):539-45. PubMed ID: 19877978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Weight gain management in patients with schizophrenia during treatment with olanzapine in association with nizatidine.
    Assunção SS; Ruschel SI; Rosa Lde C; Campos JA; Alves MJ; Bracco OL; de Lima MS
    Braz J Psychiatry; 2006 Dec; 28(4):270-6. PubMed ID: 17242805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mifepristone treatment of olanzapine-induced weight gain in healthy men.
    Gross C; Blasey CM; Roe RL; Allen K; Block TS; Belanoff JK
    Adv Ther; 2009 Oct; 26(10):959-69. PubMed ID: 19888560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.
    Lindenmayer JP; Czobor P; Volavka J; Citrome L; Sheitman B; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
    Am J Psychiatry; 2003 Feb; 160(2):290-6. PubMed ID: 12562575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.